Recent Updates
Recently added Catalysts
VOR Positive Sentiment

Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference

Thursday, May 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vor Bio will participate in the 2026 Jefferies Global Healthcare Conference, providing a corporate update during a fireside chat. The presentation is scheduled for June 3, 2026, and will be accessible via a live webcast. Vor Bio is focused on advancing its telitacicept treatment for autoimmune diseases through Phase 3 clinical development.
Price reaction · baseline $15.52 (2026-05-27 close) · hit after-hours · 1 other VOR headline(s) in the window, move may be shared
day 0 close · peak
-3.3%

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Vor Bio is actively participating in a major healthcare conference.
  • The company is advancing its novel treatment for autoimmune diseases.
  • A live webcast will provide accessibility to investors and stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+442%
120-day peak, hindsight
Typical move
18.8%
average across 6 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
Telitacicept
Phase 3 · Primary Sjogren's Disease

Full Press Release Details

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY.
Presentation: Wednesday, June 3, 2026 at 9:55am – 10:25 am ET
A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.
About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visitwww.vorbio.com.

Frequently Asked Questions

When will Vor Bio present at the Jefferies Conference?

Vor Bio will present on June 3, 2026, from 9:55 am to 10:25 am ET.

How can I access the Vor Bio presentation?

The presentation will be available via a live webcast on Vor's investor website.

What is Vor Bio's main focus?

Vor Bio is focused on transforming the treatment of autoimmune diseases.

What is telitacicept?

Telitacicept is a novel dual-target fusion protein in Phase 3 clinical development.

ShareAdd on Google
Tags: VOR Viatris Investor Conferences Healthcare Vor Bio Jefferies Conference autoimmune diseases telitacicept clinical-stage biotechnology
Last updated: May 28, 2026

Conference Timeline

Nov 11, 2025
UBS Global Healthcare Conference
8:45 AM ET • Fireside Chat
Nov 18, 2025
Jefferies Global Healthcare
11:30 AM GMT • London

Biotech snapshot

Cash runway
$466M liquidity · $8M/mo burn
~55 mo
Minimal dilution risk
Lead asset
TelitaciceptPhase 3
Primary Sjogren's Disease →

Catalyst track record

+442%
best trade around VOR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VOR.

See every catalyst's timing & PoA →